A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
AI Deep Learning Model Enhances Echocardiogram RV Assessment and Prognosis
Researchers developed DROID-RV, a deep learning tool that automates right ventricular assessment from echocardiograms, showing strong prognostic links with cardiovascular outcomes.